Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study
Ran Reshef(Abramson Cancer Center), David L. Porter(Chapman University), James K. Mangan(UC San Diego Health System), Edward A. Stadtmauer(University of Pennsylvania), Robert H. Vonderheide(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Robin Blauser(University of Pennsylvania), James A. Hoxie(University of Pennsylvania), Lee P. Richman(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Austin P. Huffman, Alex Ganetsky(Hospital of the University of Pennsylvania), Edward P. Acosta(University of Alabama at Birmingham), Selina M. Luger(University of Pennsylvania)
Cited by 4
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898